Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

4S: Scandinavian Simvastatin Survival Study

principal contacts

John Kjekhus (University of Oslo)

Terje Pedersen (University of Oslo)

Lars Wilhelmsen (University of Gothenburg)

Yale Mitchel (Merck &Co. Inc)

Andrew Tershakovec (Merck and Co. Inc.)

data custodian

Merck & Co. Inc

funding

Merck & Co. Inc

key publications

Design paper: Am J Cardiol 1993; 71: 393-400

Main results: Lancet 1994; 344:1383-89

Cost effectiveness:  Eur Heart J 1996; 17(7): 1001-7

5 year follow-up:  Am J Cardiol 2000; 86(3): 257-62

10 year follow-up:  Lancet 2004; 364(9436): 771-7

Safety:  Arch Intern Med 1996; 156(18); 2095-92

Those with diabetes:  Diabetes Care 1997; 20(4): 614-20